8:01AM Incyte achieves $50 mln milestone as Oral JAK1/JAK2 inhibitor Baricitinib advances into Phase III development for rheumatoid arthritis (INCY) 16.63 : Co announces it has earned a $50 mln milestone payment from Eli Lilly (LLY) based on the formal initiation of the rheumatoid arthritis Phase III program for baricitinib, Incyte's oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III program is being conducted by Lilly as part of the exclusive worldwide License, Development and Commercialization Agreement for baricitinib.
Market Data 
Markets 
AI
